Therapy for Gaucher disease: don't stop thinking about tomorrow (Q36644685)

15 August 2017

1 reference

title

Therapy for Gaucher disease: don't stop thinking about tomorrow (English)

1 reference

15 August 2017

1 reference

Ellen Sidransky

1 reference

15 August 2017

Mary E LaMarca

series ordinal

1 reference

15 August 2017

Edward I Ginns

series ordinal

1 reference

15 August 2017

publication date

3 November 2006

1 reference

Molecular Genetics and Metabolism

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

122-125

1 reference

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

The clinical course of treated and untreated Gaucher disease. A study of 45 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Lysosomal storage diseases: natural history and ethical and economic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Gaucher disease and the clinical experience with substrate reduction therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Long-term expression, systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primary myoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Long-term expression of the human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Retrovirus-Mediated Transfer of the cDNA for Human Glucocerebrosidase into Peripheral Blood Repopulating Cells of Patients with Gaucher's Disease. University of Wisconsin, Madison, Wisconsin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Gene therapy for lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Chemical chaperones--a new concept in drug research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Endothelial endocytic pathways: gates for vascular drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

Bispecific antibodies as novel bioconjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.09.007

10.1016/J.YMGME.2006.09.007

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference